[
    [
        {
            "time": "",
            "original_text": "万泰生物(60392)首次覆盖报告：传统IVD业务结构优化 创新疫苗增长可期",
            "features": {
                "keywords": [
                    "万泰生物",
                    "IVD业务",
                    "结构优化",
                    "创新疫苗",
                    "增长可期"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "万泰生物(60392)首次覆盖报告：传统IVD业务结构优化 创新疫苗增长可期",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]